173406-70-7

Basic information

• Product Name: 3-BROMO-N-HYDROXY-BENZAMIDINE
• Synonyms: 3-BROMO-N-HYDROXY-BENZAMIDINE;(E)-3-Bromo-N'-hydroxybenzimidamide;3-broMo-N'-hydroxybenzene-1-carboxiMidaMide;3-bromo-N-hydroxybenzimidamide
• CAS NO: 173406-70-7
• Molecular Formula: C₇H₇BrN₂O
• Molecular Weight: 215.05
• Mol File: 173406-70-7.mol
• Article Data: 26

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-BROMO-N-HYDROXY-BENZAMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMO-N-HYDROXY-BENZAMIDINE(173406-70-7)
• EPA Substance Registry System: 3-BROMO-N-HYDROXY-BENZAMIDINE(173406-70-7)

Safety Data

• Hazardous Substances Data: 173406-70-7(Hazardous Substances Data)

Usage

General Description

3-Bromo-N-hydroxy-benzamidine is a chemical compound that belongs to the class of benzamidines. It is an organic compound with the molecular formula C7H7BrN2O and a molecular weight of 214.05 g/mol. 3-BROMO-N-HYDROXY-BENZAMIDINE is a bromo-substituted derivative of N-hydroxy-benzamidine and is commonly used as a reagent in organic synthesis and pharmaceutical research. It is also known for its potential use as an anticoagulant and anti-thrombotic agent. 3-Bromo-N-hydroxy-benzamidine is a white to off-white solid that is sparingly soluble in water, and its precise chemical properties make it a valuable component in various chemical and pharmaceutical applications.

Upstream product

• 6952-59-6 3-cyanobromobenzene 
• 51873-95-1 3-bromobenzaldehyde oxime 
• 3132-99-8 m-bromobenzoic aldehyde 

Downstream Products

• 160377-57-1 3-(3-bromophenyl)-5-methyl-1,2,4-oxadiazole 

Relevant articles and documents

Imidazole hydrochloride promoted synthesis of 3,5-disubstituted-1,2,4-oxadiazoles

Imidazole hydrochloride as an additive promotes the reaction of amidoximes and DMA derivatives to generated 3,5-disubstituted-1,2,4-oxadiazoles in low to excellent yields without the use of coupling reagents, oxidants, strong acids or bases and other additives.

KCNT1 INHIBITORS AND METHODS OF USE

The present invention is directed to, in part, compounds and compositions useful for preventing and/or treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene (e.g., KCNT1). Methods of treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene such as KCNT1 are also provided herein.

NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME

The present technology provides triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).